About the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta

As one of the most active institutions in the country in pediatric clinical trial enrollment, our clinical research program offers patients access to more than 400 clinical studies, including some of the most novel diagnostic and treatment options in the country. Our physicians participate—and often play leadership roles—in all of the major national collaborative research consortia geared toward the early clinical development of promising therapies for cancer and blood disorder treatment. Our goal is to provide an open clinical trial for every child we treat so our patients do not have to travel to other states for innovative care. We also serve as a referral center for patients from across Georgia and throughout the U.S. who otherwise might not have access to Phase I and II trials.

The Aflac Cancer and Blood Disorders Center has become one of the best childhood cancer programs in the country. We are proud to benefit from important community support that helps catapult our research efforts and makes it possible for us to care for children with every type of pediatric cancer and blood disorder."

Douglas K. Graham, MD, PhD, Director, Aflac Cancer and Blood Disorders Center.

The Aflac Cancer and Blood Disorders Center is one of the leading childhood cancer and blood disorders programs in the country, diagnosing 522 new cancer patients in 2021. Combining the latest proven technology and research with a caring, child-friendly approach, the Aflac Cancer and Blood Disorders Center is a top choice for the treatment of common and complex cancer, and blood disorders.

Additionally, the Aflac Cancer and Blood Disorders Center is uniquely positioned to leverage the vast knowledge and capabilities in Atlanta through collaborative relationships with Emory University, Winship Cancer Institute, Georgia Tech, Morehouse University School of Medicine and the Centers for Disease Control and Prevention (CDC). Working together, we continue to seek personalized cures for the most challenging childhood oncologic and hematologic conditions.